To this end, we extended our investigations beyond DOX, one of the standard chemotherapeutic agents used to treat post-surgical recurrent CS [79], by also examining the effects of SMI1182, a small molecule inhibitor of ASPH, and BEZ235, a potent inhibitor of PI3K/mTOR [80,81]. The gene discussed is ASPH; the disease is Cowden syndrome 1.